Medical Pharmacology: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-01 — Definition, Classification, and Pathophysiology

Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-01 — Definition, Classification, and Pathophysiology
Tier: Tier 3

1. A 61-year-old man with hypertension, stage 4 CKD (eGFR 22 mL/min/1.73m²), and hyperkalemia (K+ 5.8 mEq/L) on lisinopril presents with BP 168/102 mmHg. His nephrologist discontinues the lisinopril due to the hyperkalemia and starts amlodipine. Three months later BP is 154/98 mmHg and urine albumin-to-creatinine ratio (ACR) has risen from 320 to 610 mg/g. Which of the following best explains the worsening proteinuria and guides the next step?

A) The amlodipine is causing direct glomerular toxicity through calcium overload of podocytes at the high doses required in advanced CKD, and should be replaced with a thiazide diuretic
B) Removal of ACE inhibitor-mediated efferent arteriole vasodilation has allowed intraglomerular pressure to rise, worsening glomerular hypertension and increasing protein leak; the hyperkalemia must be addressed to allow reintroduction of RAAS blockade — options include a potassium binder such as patiromer or sodium zirconium cyclosilicate to permit safe ACE inhibitor or ARB use despite advanced CKD
C) The proteinuria rise reflects progression of the underlying CKD independent of antihypertensive therapy, and no pharmacological intervention other than continued BP lowering is indicated
D) A loop diuretic should be added to lower BP further, as the residual proteinuria reflects inadequate systemic BP control rather than intraglomerular pressure changes
E) The proteinuria rise indicates the amlodipine has triggered a secondary RAAS activation that is more harmful than the original ACE inhibitor-induced hyperkalemia, and sacubitril-valsartan should be initiated to address both BP and RAAS-mediated proteinuria simultaneously

ANSWER: B

Rationale:

This question asked you to identify why removing RAAS blockade in a CKD patient with hyperkalemia worsens proteinuria and determine the appropriate next step. Option B is correct: in advanced CKD, intraglomerular pressure is partially controlled by ACE inhibitor-mediated efferent arteriole vasodilation, which reduces the hydraulic pressure driving protein across the filtration barrier. When the ACE inhibitor is removed, efferent tone returns and intraglomerular pressure rises — exactly reversing the renal protective mechanism. The result is worsening glomerular hypertension and increased proteinuria. The correct clinical response is not to abandon RAAS blockade permanently but to address the hyperkalemia barrier. Potassium binders — patiromer and sodium zirconium cyclosilicate (SZC) — are specifically indicated to enable or sustain RAAS inhibitor therapy in CKD patients with hyperkalemia. Both have been studied in this indication (AMBER (a trial of patiromer enabling continued RAAS inhibitor therapy in resistant hypertension with CKD and hyperkalemia) trial for patiromer, and clinical experience with SZC) and allow reintroduction of ACE inhibitors or ARBs with continued potassium management.

Option A: Option A is incorrect — amlodipine does not cause podocyte toxicity through calcium overload at therapeutic doses; this mechanism is fabricated.
Option C: Option C is incorrect — the temporal correlation between ACE inhibitor discontinuation and proteinuria worsening is pharmacologically explained and not merely natural progression.
Option D: Option D is incorrect — while BP control is important, the dominant mechanism here is intraglomerular pressure from loss of efferent vasodilation, not systemic BP inadequacy alone.
Option E: Option E is incorrect — sacubitril-valsartan is contraindicated in patients with prior ACE inhibitor angioedema and should be used with caution in advanced CKD; moreover the clinical priority is re-establishing safe RAAS blockade, not adding neprilysin inhibition.

2. A 53-year-old woman with hypertension, migraine with aura, and no other comorbidities presents for antihypertensive selection. BP is 154/96 mmHg on no medications. She reports that her migraines are triggered by stress and occur approximately three times per month. Which of the following antihypertensive agents also has established efficacy for migraine prophylaxis, and what is the shared mechanistic basis?

A) Amlodipine, because dihydropyridine CCBs prevent migraine by blocking L-type calcium channels in trigeminal ganglion neurons, reducing calcitonin gene-related peptide (CGRP) release and preventing cortical spreading depression
B) Losartan, because AT1 (angiotensin type 1) receptor blockade in cerebral vasculature prevents the vasoconstriction that initiates cortical spreading depression, and all ARBs have demonstrated equivalent migraine prophylaxis efficacy in randomized controlled trials
C) Propranolol or metoprolol, because beta-adrenergic receptor blockade reduces sympathetically mediated cerebrovascular reactivity and modulates serotonergic transmission in the brainstem — mechanisms relevant to migraine pathophysiology; beta-blockers are first-line pharmacological migraine prophylaxis with the strongest evidence base
D) Hydrochlorothiazide, because thiazide-mediated reduction in extracellular volume lowers intracranial pressure, which reduces the pressure waves triggering cortical spreading depression in migraine
E) Lisinopril, because ACE inhibitor-mediated bradykinin accumulation in the CNS activates inhibitory pathways that prevent cortical spreading depression and trigeminal sensitization, and lisinopril has the strongest evidence among all antihypertensives for migraine prophylaxis

ANSWER: C

Rationale:

This question asked you to identify the antihypertensive agent with established dual utility in hypertension and migraine prophylaxis. Option C is correct: beta-blockers — particularly propranolol (non-selective) and metoprolol (beta-1 selective) — are Level A evidence, first-line pharmacological agents for migraine prophylaxis in major headache society guidelines. Their mechanism in migraine is not fully elucidated but involves reduction of sympathetically mediated cerebrovascular reactivity, modulation of serotonergic pathways in the dorsal raphe nucleus, and possibly suppression of cortical spreading depression. For this patient, a beta-blocker achieves two therapeutic goals through a single agent. One important clinical caveat: propranolol and metoprolol are generally avoided in patients with migraine with aura who also have cardiovascular risk factors due to the independent elevated stroke risk associated with migraine with aura — the physician should assess overall stroke risk before selecting a non-selective beta-blocker.

Option A: Option A is incorrect — dihydropyridine CCBs, including amlodipine, do not have Level A evidence for migraine prophylaxis; verapamil (a non-dihydropyridine CCB) has modest evidence for cluster headache, not migraine.
Option B: Option B is incorrect — candesartan has some evidence for migraine prophylaxis in small trials, but the evidence is not as strong as for beta-blockers and it is not a first-line recommendation; not all ARBs have demonstrated equivalent prophylaxis efficacy.
Option D: Option D is incorrect — thiazide diuretics do not reduce intracranial pressure in the manner described and have no established role in migraine prophylaxis.
Option E: Option E is incorrect — while lisinopril has been studied for migraine prophylaxis in one small trial, it is not guideline-recommended as a first-line agent and does not have the evidence base of beta-blockers.

3. A 67-year-old man with hypertension and newly diagnosed heart failure with reduced ejection fraction (HFrEF, EF 32%) has BP of 148/90 mmHg on amlodipine 10 mg daily. His cardiologist initiates sacubitril-valsartan. The patient asks whether his amlodipine can be continued. Which of the following most accurately addresses this question and explains the pharmacological reasoning?

A) Amlodipine must be discontinued when sacubitril-valsartan is started because the combination causes excessive bradykinin accumulation through additive neprilysin and ACE inhibition, producing severe vasodilation and risk of angioedema
B) Amlodipine should be replaced with a beta-blocker because dihydropyridine CCBs are contraindicated in HFrEF due to their negative inotropic effect, which worsens systolic dysfunction and precipitates acute decompensation
C) Sacubitril-valsartan and amlodipine cannot be used together because valsartan and amlodipine compete for the same CYP3A4 metabolic pathway, producing a pharmacokinetic interaction that doubles plasma levels of both drugs and requires dose reduction of each
D) Amlodipine can be continued alongside sacubitril-valsartan — dihydropyridine CCBs have no significant negative inotropic effect at therapeutic doses and are not contraindicated in HFrEF; amlodipine and felodipine are the only CCBs studied specifically in heart failure patients and found to be hemodynamically neutral, and continuing amlodipine provides additional BP control
E) Amlodipine should be discontinued because calcium channel blockade interferes with the natriuretic peptide signaling that sacubitril-valsartan depends upon — blocking L-type channels prevents BNP (B-type natriuretic peptide)-mediated cGMP generation in cardiac myocytes, negating the therapeutic benefit of neprilysin inhibition

ANSWER: D

Rationale:

This question asked you to determine whether amlodipine can be continued when sacubitril-valsartan is initiated in HFrEF. Option D is correct: dihydropyridine CCBs — amlodipine and felodipine specifically — are the only CCBs that have been evaluated in patients with heart failure and found to be hemodynamically neutral (V-HeFT III (amlodipine in heart failure with reduced EF, demonstrating hemodynamic neutrality) for amlodipine, F-HeFT for felodipine). They do not significantly depress myocardial contractility at therapeutic doses due to their high vascular selectivity compared to non-dihydropyridine CCBs. They are not contraindicated in HFrEF and can be used for additional BP or angina control when needed. Sacubitril-valsartan is compatible with continued amlodipine use.

Option A: Option A is incorrect — amlodipine does not inhibit ACE or neprilysin; there is no additive bradykinin accumulation mechanism with amlodipine plus sacubitril-valsartan.
Option B: Option B is incorrect — the contraindication to CCBs in HFrEF applies to non-dihydropyridine CCBs (diltiazem, verapamil) which have significant negative inotropic and chronotropic effects; dihydropyridine CCBs like amlodipine are not contraindicated.
Option C: Option C is incorrect — while valsartan is metabolized in part by CYP3A4, the pharmacokinetic interaction with amlodipine (also CYP3A4) is not clinically significant at standard doses; this is not a reason to discontinue either agent.
Option E: Option E is incorrect — L-type calcium channel blockade in cardiac myocytes does not interfere with natriuretic peptide-mediated cGMP signaling in the manner described; the BNP/cGMP pathway is distinct from voltage-gated calcium channel activity.

4. A 44-year-old woman with hypertension and systemic lupus erythematosus (SLE) controlled on hydroxychloroquine presents with BP 158/98 mmHg and a urine ACR of 280 mg/g. Renal biopsy confirms lupus nephritis Class III. Which of the following best describes the antihypertensive approach in this patient, and why is agent selection influenced by the renal diagnosis?

A) Diuretics are the first-line antihypertensive in lupus nephritis because the dominant mechanism is aldosterone-mediated sodium retention from immune complex deposition in the collecting duct, and thiazides address this directly
B) Beta-blockers are preferred in lupus nephritis because they reduce renal sympathetic tone and decrease the inflammatory cytokine storm that drives immune-mediated glomerular injury
C) An ACE inhibitor or ARB is the preferred antihypertensive because in addition to BP reduction, RAAS blockade reduces intraglomerular pressure, decreases proteinuria, and may slow progression of the lupus nephritis-associated glomerular injury — the same mechanism that makes RAAS blockade renoprotective in diabetic nephropathy applies to inflammatory glomerulonephritis with proteinuria
D) Calcium channel blockers are absolutely contraindicated in lupus nephritis because dihydropyridine-induced afferent vasodilation worsens hematuria by increasing glomerular capillary pressure and accelerating immune complex deposition
E) Hydralazine should be avoided in this patient because its use in SLE is associated with drug-induced lupus — a lupus-like syndrome that is distinct from SLE itself but shares some clinical features and could confound disease monitoring and management

ANSWER: E

Rationale:

This question had two valid elements requiring identification of the best combined answer. Option C correctly identifies ACE inhibitor or ARB as the preferred antihypertensive for the proteinuric glomerulonephritis — the intraglomerular pressure reduction mechanism applies to inflammatory glomerular disease as well as diabetic nephropathy, and RAAS blockade is standard of care in proteinuric lupus nephritis. Option E identifies a critical drug-specific avoidance decision: hydralazine is associated with drug-induced lupus erythematosus (DILE), a lupus-like syndrome caused by hydralazine's interference with DNA methylation in T-lymphocytes. In a patient with established SLE, introducing hydralazine creates the possibility of DILE layered on top of SLE, which complicates disease monitoring, serology interpretation, and management decisions. While hydralazine-induced DILE typically differs from SLE in its clinical features (more often spares the kidneys and CNS) and resolves with drug discontinuation, its use in a patient with known SLE is avoided whenever possible. The question asks which single option best describes the approach — Option E is the most clinically decisive answer because it identifies a specific contraindication unique to this patient's SLE diagnosis, while Option E is the best answer.

Option C: Option C states a general principle that applies broadly. For this reason
Option A: Option A is incorrect — the dominant mechanism of hypertension in lupus nephritis is RAAS activation and glomerular injury, not collecting duct aldosterone retention from immune complexes.
Option B: Option B is incorrect — beta-blockers do not reduce the cytokine-mediated inflammatory injury in lupus nephritis.
Option D: Option D is incorrect — CCBs are not contraindicated in lupus nephritis for the reasons stated; the mechanism described is fabricated.

5. A 71-year-old man with isolated systolic hypertension (ISH), moderate aortic stenosis (valve area 1.2 cm², mean gradient 28 mmHg), and no heart failure symptoms has BP of 168/72 mmHg. Which of the following most accurately describes the pharmacological challenge of treating his hypertension in the context of his aortic stenosis?

A) Aortic stenosis is not relevant to antihypertensive selection — any agent that lowers systemic BP is equally appropriate regardless of valvular pathology
B) ACE inhibitors are absolutely contraindicated in aortic stenosis because efferent arteriole vasodilation reduces coronary perfusion pressure in the hypertrophied LV, precipitating ischemia
C) Diuretics are contraindicated in all patients with aortic stenosis regardless of fluid status because any reduction in preload in the context of a fixed outflow obstruction produces cardiac arrest
D) Antihypertensive therapy in aortic stenosis requires caution because the hypertrophied, pressure-overloaded LV depends on adequate preload and afterload to maintain stroke volume across the fixed obstruction — vasodilators that abruptly reduce preload or afterload can precipitate a critical fall in cardiac output; however, BP lowering is still indicated and should be achieved gradually with agents titrated carefully, avoiding large preload-reducing agents; ACE inhibitors in moderate AS (aortic stenosis) have shown benefit in some studies
E) Beta-blockers are the only safe antihypertensive in aortic stenosis because negative chronotropy prolongs diastolic filling time, compensating for the fixed obstruction and maintaining cardiac output despite reduced preload

ANSWER: D

Rationale:

This question asked you to reason through the hemodynamic complexity of treating hypertension in the setting of moderate aortic stenosis. Option D is correct: aortic stenosis creates a fixed outflow obstruction that limits the LV's ability to augment stroke volume in response to changes in loading conditions. The hypertrophied LV is stiff and preload-dependent — it requires adequate filling to generate the pressure needed to eject across the stenotic valve. Agents that abruptly reduce preload (aggressive diuresis, nitrates) or cause a rapid fall in systemic vascular resistance (high-dose vasodilators) can precipitate a sudden fall in cardiac output and symptomatic hypotension. However, untreated hypertension in moderate AS increases afterload further, accelerates LV hypertrophy, and worsens the hemodynamic burden. The correct approach is careful, gradual BP lowering — not abandonment of treatment — with close monitoring and avoidance of drugs that cause abrupt preload reduction. ACE inhibitors in moderate (not severe) AS have been evaluated in several studies suggesting hemodynamic benefit without harm.

Option A: Option A is incorrect — aortic stenosis creates specific hemodynamic constraints that make antihypertensive selection clinically important.
Option B: Option B is incorrect — ACE inhibitors are not absolutely contraindicated in aortic stenosis; the absolute contraindication is in severe symptomatic AS where systemic vasodilation may precipitate dangerous hypotension, but moderate AS is a different clinical situation.
Option C: Option C is incorrect — diuretics are not contraindicated in all AS; careful diuresis in volume-overloaded AS patients is safe and sometimes necessary.
Option E: Option E is incorrect — beta-blockers are not the only safe antihypertensive in AS; and while they prolong diastolic filling time, they do not "compensate for the fixed obstruction" in the manner described.

6. A 48-year-old woman with hypertension and Raynaud's phenomenon (episodic digital vasospasm precipitated by cold) presents with BP 158/96 mmHg. She is asking about antihypertensive options. Which of the following correctly identifies the agent most likely to worsen her Raynaud's symptoms and the preferred antihypertensive alternative?

A) ACE inhibitors most likely worsen Raynaud's because bradykinin accumulation causes paradoxical vasoconstriction in digital arterioles; a beta-blocker is the preferred alternative
B) Thiazide diuretics most likely worsen Raynaud's because volume depletion activates sympathetic vasoconstriction in digital vessels; a CCB is the preferred alternative
C) Non-selective beta-blockers most likely worsen Raynaud's by blocking beta-2-mediated vasodilation in peripheral arterioles, leaving alpha-1-mediated vasoconstriction unopposed in the digits and precipitating or worsening vasospastic attacks; dihydropyridine CCBs such as amlodipine or nifedipine are the preferred antihypertensive because they directly vasodilate peripheral arterioles and are established treatment for both hypertension and Raynaud's phenomenon
D) ARBs most likely worsen Raynaud's because AT2 (angiotensin type 2) receptor blockade, which occurs as an off-target effect of ARBs at high doses, eliminates AT2-mediated digital vasodilation during cold exposure
E) Dihydropyridine CCBs most likely worsen Raynaud's because their preferential dilation of afferent arterioles in the kidney causes a redistribution of blood flow away from peripheral digital vessels, worsening digital ischemia during cold exposure

ANSWER: C

Rationale:

This question asked you to identify the antihypertensive most likely to worsen Raynaud's and the preferred alternative. Option C is correct on both counts: non-selective beta-blockers (propranolol, nadolol, carvedilol) block beta-2 adrenergic receptors in peripheral arterioles. Beta-2 stimulation normally produces vasodilation in peripheral vessels. When beta-2 receptors are blocked, the vasoconstrictor effect of sympathetic alpha-1 stimulation is left unopposed, increasing peripheral vascular resistance in the digits and worsening or precipitating Raynaud's attacks — particularly during cold or stress-induced sympathetic activation. Even cardioselective beta-1 blockers can worsen Raynaud's at higher doses as beta-1 selectivity diminishes. Dihydropyridine CCBs are both effective antihypertensives and established first-line pharmacological therapy for Raynaud's phenomenon — they directly block L-type calcium channels in vascular smooth muscle, reducing vasospastic tone in digital arterioles. Nifedipine and amlodipine are the most studied.

Option A: Option A is incorrect — ACE inhibitors do not cause paradoxical digital vasoconstriction through bradykinin and are not a preferred avoidance drug in Raynaud's.
Option B: Option B is incorrect — while sympathetic activation from volume depletion could theoretically worsen Raynaud's, thiazide diuretics are not specifically contraindicated or identified as a primary concern in Raynaud's management.
Option D: Option D is incorrect — ARBs block AT1, not AT2 receptors, and this mechanism for worsening Raynaud's is fabricated.
Option E: Option E is incorrect — dihydropyridine CCBs are the preferred treatment, not the agent to avoid, in Raynaud's with hypertension.

7. A 55-year-old man with hypertension is found on routine lab work to have a serum potassium of 6.1 mEq/L. He is on lisinopril 20 mg daily, spironolactone 25 mg daily, and trimethoprim-sulfamethoxazole (TMP-SMX) for a urinary tract infection prescribed 5 days ago. His baseline potassium before the antibiotic was 4.9 mEq/L. Renal function is stable with eGFR 58. Which of the following most accurately explains the hyperkalemia and identifies the most appropriate immediate management?

A) The hyperkalemia reflects disease progression of his underlying hypertension causing acute tubular injury; both the ACE inhibitor and spironolactone should be discontinued permanently and he should be referred to nephrology
B) TMP-SMX causes hyperkalemia by blocking the epithelial sodium channel (ENaC) in the collecting duct — the same mechanism as amiloride — thereby inhibiting sodium reabsorption and potassium secretion; in a patient already on two agents that suppress aldosterone-mediated potassium excretion (ACE inhibitor and spironolactone), the addition of a third ENaC-blocking agent creates a clinically dangerous triple potassium-sparing combination; TMP-SMX should be discontinued and an alternative antibiotic prescribed
C) The hyperkalemia is caused solely by TMP-SMX-induced acute kidney injury that has reduced GFR below the threshold for adequate potassium excretion; the lisinopril and spironolactone are not contributing
D) The spironolactone dose should be doubled to correct the hyperkalemia through a paradoxical stimulation of aldosterone-independent potassium excretion pathways
E) The hyperkalemia reflects a drug-drug interaction between TMP-SMX and lisinopril at the CYP2D6 level, producing toxic plasma lisinopril accumulation that overwhelms the renal potassium excretion capacity

ANSWER: B

Rationale:

This question asked you to identify the mechanism of TMP-SMX-associated hyperkalemia in a patient already on multiple potassium-sparing agents. Option B is correct: trimethoprim, the active component of TMP-SMX, blocks ENaC (the epithelial sodium channel) in the collecting duct principal cells — the identical mechanism as amiloride and triamterene (potassium-sparing diuretics). By blocking ENaC, trimethoprim inhibits the sodium entry that drives the electrochemical gradient for potassium secretion in principal cells. In a patient already taking an ACE inhibitor (which suppresses aldosterone-mediated ENaC upregulation) and spironolactone (which blocks the mineralocorticoid receptor that drives ENaC expression), adding trimethoprim creates a triple combination blocking potassium excretion at three complementary levels: reduced aldosterone production (ACE inhibitor), blocked aldosterone receptor (spironolactone), and blocked ENaC channel directly (trimethoprim). The result is clinically significant hyperkalemia. The appropriate management is discontinuation of TMP-SMX and substitution with an antibiotic that does not block ENaC — nitrofurantoin or a fluoroquinolone depending on susceptibility.

Option A: Option A is incorrect — the hyperkalemia is pharmacologically explained and does not represent irreversible tubular injury; permanent discontinuation of RAAS blockade is not indicated.
Option C: Option C is incorrect — TMP-SMX does not typically cause acute kidney injury at standard doses; the mechanism is ENaC blockade, not nephrotoxicity.
Option D: Option D is incorrect — doubling spironolactone would worsen hyperkalemia, not correct it; the framing of a "paradoxical" potassium-excreting effect is fabricated.
Option E: Option E is incorrect — the mechanism is ENaC blockade by trimethoprim, not a CYP2D6 interaction; lisinopril is not significantly metabolized by CYP2D6.

8. A 62-year-old woman with hypertension, type 2 diabetes, and a BMI of 36 is referred after failing three antihypertensive agents including a maximal-dose ACE inhibitor, CCB, and thiazide diuretic with confirmed adherence. Aldosterone-to-renin ratio is normal. She has moderate obstructive sleep apnea and is non-compliant with continuous positive airway pressure (CPAP). Fasting aldosterone level is in the upper-normal range. Which of the following best explains why her aldosterone level being in the upper-normal range is still pathophysiologically relevant to her resistant hypertension?

A) Upper-normal aldosterone in the context of obesity-related resistant hypertension represents physiologically inappropriate aldosterone levels for the degree of sodium loading present — in states of sodium excess and expanded volume, aldosterone should be suppressed below normal rather than maintained at the upper-normal range; this relative aldosterone excess sustains volume expansion and supports the mechanistic basis for spironolactone efficacy in resistant hypertension even without a formally elevated aldosterone-to-renin ratio (ARR)
B) Upper-normal aldosterone levels indicate that primary aldosteronism has been excluded and the PATHWAY-2 (a randomized crossover trial demonstrating spironolactone superiority as fourth-line agent in resistant hypertension) trial results supporting spironolactone do not apply to patients with normal ARR; resistant hypertension in this patient must be driven entirely by the obstructive sleep apnea (OSA) and the only effective management is improved CPAP compliance
C) Upper-normal aldosterone reflects normal adrenal function and confirms the resistant hypertension is purely related to obesity-driven volume expansion that responds only to loop diuretic therapy rather than mineralocorticoid receptor antagonism
D) Aldosterone levels in the upper-normal range trigger AT2 receptor upregulation in the vasculature, producing a paradoxical vasoconstriction that standard antihypertensives cannot overcome without specific AT2 blockade
E) The upper-normal aldosterone is clinically irrelevant because spironolactone's benefit in resistant hypertension is entirely independent of aldosterone levels and is mediated through direct beta-1 receptor blockade in the juxtaglomerular apparatus

ANSWER: A

Rationale:

This question asked you to interpret the significance of upper-normal aldosterone in the context of obesity-related resistant hypertension and the mechanistic basis for mineralocorticoid receptor antagonist efficacy. Option A is correct: a key insight from the pathophysiology of resistant hypertension is that aldosterone levels should not be interpreted in isolation but relative to the sodium and volume status of the patient. In a patient with obesity, volume expansion, and high dietary sodium intake, the RAAS should be suppressed — renin and aldosterone should both be at the low end of normal. When aldosterone remains in the upper-normal range in this context, it represents inappropriate aldosterone activity relative to the degree of volume expansion. This relative excess — even without formal ARR elevation or frank hyperaldosteronism — maintains inappropriate sodium retention and volume expansion that conventional antihypertensives cannot fully overcome. This is the physiological basis for why the PATHWAY-2 trial found spironolactone beneficial in resistant hypertension patients regardless of whether formal primary aldosteronism was present — the dominant mechanism is relative aldosterone excess driving volume-dependent resistant hypertension.

Option B: Option B is incorrect — the PATHWAY-2 findings do apply to resistant hypertension patients with normal ARR; the trial did not require a formally elevated ARR for spironolactone to be beneficial.
Option C: Option C is incorrect — the mechanism of relative aldosterone excess makes mineralocorticoid receptor antagonism specifically appropriate, not just loop diuretics.
Option D: Option D is incorrect — upper-normal aldosterone does not trigger AT2-mediated paradoxical vasoconstriction; this mechanism is fabricated.
Option E: Option E is incorrect — spironolactone's benefit in resistant hypertension is mediated through mineralocorticoid receptor antagonism, not beta-1 blockade in the JGA.

9. A 58-year-old man with hypertension, established coronary artery disease, and a prior anterior STEMI 2 years ago (EF recovered to 48%) is on metoprolol succinate, aspirin, and atorvastatin. His BP is 146/88 mmHg. His cardiologist wants to add an antihypertensive that provides the greatest additional cardiovascular outcome benefit beyond BP lowering in this specific post-MI setting. Which of the following agents is most appropriate and why?

A) Amlodipine, because dihydropyridine CCBs reduce coronary vasospasm in post-MI patients through direct coronary arteriolar vasodilation, providing specific anti-ischemic benefit independent of BP lowering
B) Hydrochlorothiazide, because thiazide-mediated volume reduction lowers cardiac preload, reducing myocardial oxygen demand in post-MI patients with residual ischemia more effectively than any other drug class
C) Spironolactone, because mineralocorticoid receptor blockade is the most evidence-based pharmacological addition in post-MI patients with recovered EF and is recommended in all post-MI patients regardless of whether heart failure symptoms are present
D) An ACE inhibitor such as ramipril or lisinopril, because post-MI trials (HOPE (a trial of ramipril vs placebo in high-risk vascular disease patients, demonstrating cardiovascular outcome benefit beyond BP lowering), AIRE, TRACE) have demonstrated that ACE inhibition reduces cardiovascular death, non-fatal MI, and stroke in patients with established coronary artery disease and LV dysfunction through mechanisms including attenuation of adverse LV remodeling, plaque stabilization effects of RAAS blockade, and anti-atherogenic bradykinin accumulation — benefits that are independent of and additive to BP lowering
E) Losartan, because the LIFE (a trial of losartan vs atenolol in hypertension with LVH) trial demonstrated that losartan provides superior cardiovascular outcome benefit compared to all other antihypertensive classes in patients with hypertension and established coronary artery disease

ANSWER: D

Rationale:

This question asked you to identify the antihypertensive providing the greatest additional cardiovascular outcome benefit in a specific post-MI patient. Option D is correct: ACE inhibitors have the most robust evidence base for cardiovascular outcome benefit in patients with established CAD, prior MI, and LV dysfunction — even when EF has partially recovered. The HOPE trial (ramipril vs placebo in high-risk patients with vascular disease or diabetes) demonstrated a 22% relative risk reduction in the combined endpoint of cardiovascular death, MI, and stroke beyond what BP lowering alone would predict. AIRE (ramipril in acute MI with clinical heart failure) and TRACE (trandolapril post-MI) demonstrated similar survival benefit. The mechanisms extend beyond BP lowering: RAAS blockade attenuates adverse LV remodeling through anti-fibrotic effects, stabilizes atherosclerotic plaques through anti-inflammatory and anti-oxidative mechanisms, and bradykinin accumulation enhances endothelial nitric oxide (NO) production and fibrinolysis. ACE inhibitors are standard of care in post-MI patients with LV dysfunction.

Option A: Option A is incorrect — while CCBs are reasonable antihypertensives in stable CAD, they have not demonstrated the mortality benefit in post-MI patients that ACE inhibitors have; non-dihydropyridine CCBs are avoided in LV dysfunction.
Option B: Option B is incorrect — thiazides provide good BP lowering but do not have the specific post-MI remodeling benefit of ACE inhibitors.
Option C: Option C is incorrect — spironolactone (eplerenone) is indicated post-MI in patients with LV dysfunction and EF below 40% or heart failure symptoms (EPHESUS (a trial of eplerenone post-MI in patients with LV dysfunction and heart failure) trial); this patient's EF has recovered to 48% and he is asymptomatic, so the EPHESUS indication does not apply.
Option E: Option E is incorrect — the LIFE trial compared losartan to atenolol in patients with left ventricular hypertrophy (LVH) and did not establish losartan superiority over all antihypertensives in all post-MI patients; this framing is an overstatement.

10. A 39-year-old woman with hypertension, a 15-pack-year smoking history, and newly discovered bilateral adrenal incidentalomas (both less than 2 cm, non-enhancing, lipid-rich on CT) is evaluated. Her aldosterone-to-renin ratio is normal, plasma metanephrines are normal, and overnight dexamethasone suppression test is normal. Her BP is 162/102 mmHg on no medications. Which of the following best describes the relationship between her bilateral adrenal incidentalomas and her hypertension, and the appropriate pharmacological approach?

A) Bilateral non-functioning adrenal incidentalomas are a direct cause of her hypertension through subclinical cortisol excess that is not detected by the overnight dexamethasone test; she requires 24-hour urinary cortisol measurement before any antihypertensive is initiated
B) Bilateral non-functioning adrenal incidentalomas confirmed by normal biochemical workup (normal ARR, normal metanephrines, normal dexamethasone suppression) are incidental findings not causally responsible for her hypertension; she should be treated as having primary hypertension with standard first-line antihypertensive therapy, with ongoing surveillance of the incidentalomas per endocrinology guidelines
C) Bilateral adrenal incidentalomas always indicate bilateral adrenal hyperplasia causing subclinical primary aldosteronism; even with a normal ARR, mineralocorticoid receptor blockade with spironolactone should be initiated empirically before standard antihypertensives
D) The adrenal incidentalomas represent metastatic disease from a smoking-related primary malignancy; antihypertensive therapy should be deferred until oncological evaluation is complete
E) Bilateral adrenal incidentalomas in a hypertensive patient always require adrenalectomy before pharmacological therapy is initiated, as leaving adrenal tissue in place will undermine the efficacy of any antihypertensive drug class through persistent adrenal hormone secretion

ANSWER: B

Rationale:

This question asked you to correctly interpret the clinical significance of bilateral adrenal incidentalomas after thorough biochemical workup and determine the appropriate pharmacological approach. Option B is correct: adrenal incidentalomas are increasingly common findings on cross-sectional imaging performed for other indications, detected in approximately 2–3% of CT scans with increasing prevalence with age. The standard evaluation of adrenal incidentalomas includes biochemical screening for functionality — pheochromocytoma (plasma metanephrines or 24-hour urinary catecholamines), primary aldosteronism (ARR), and autonomous cortisol secretion (overnight dexamethasone suppression test). When all three screens are normal and the imaging characteristics are reassuring (lipid-rich, non-enhancing, less than 4 cm), the incidentalomas are classified as non-functioning and are managed with interval imaging surveillance rather than intervention. They are not causal contributors to her hypertension. Her hypertension should be treated as primary hypertension with standard pharmacological therapy.

Option A: Option A is incorrect — while some guidelines recommend a 24-hour urinary free cortisol or late-night salivary cortisol as additional testing for possible mild autonomous cortisol secretion, this patient has had the standard overnight dexamethasone suppression test which is normal; the incidentalomas do not prevent treatment initiation.
Option C: Option C is incorrect — bilateral incidentalomas with a normal ARR are not empirically treated with spironolactone without biochemical confirmation of aldosterone excess.
Option D: Option D is incorrect — bilateral lipid-rich non-enhancing adrenal incidentalomas under 2 cm have a very low probability of malignancy or metastasis; the CT characteristics are reassuring, and oncological referral is not the priority clinical action for these specific imaging findings.
Option E: Option E is incorrect — non-functioning incidentalomas do not require adrenalectomy before antihypertensive pharmacotherapy.

11. A 66-year-old man with hypertension, CKD stage 3b, and hypertriglyceridemia is on lisinopril and chlorthalidone. His BP is 144/88 mmHg and his most recent fasting triglycerides are 680 mg/dL. His physician considers replacing the chlorthalidone with a different antihypertensive to reduce his metabolic burden. Which of the following most accurately characterizes the metabolic effects of thiazide diuretics that are relevant to this decision, and identifies the most appropriate replacement?

A) Thiazide diuretics have no metabolic effects at standard doses; the hypertriglyceridemia is unrelated to chlorthalidone and the drug should be continued
B) Thiazide diuretics cause hypertriglyceridemia through direct hepatic very-low-density lipoprotein (VLDL) overproduction mediated by chloride channel activation in hepatocytes; replacing with a loop diuretic eliminates this hepatic mechanism
C) Thiazide diuretics cause mild elevation in serum triglycerides and LDL cholesterol through incompletely understood mechanisms including insulin resistance and altered hepatic lipid metabolism; however, at standard doses these metabolic effects are modest and rarely contraindicate use; in a patient with severe hypertriglyceridemia (680 mg/dL), the contribution of chlorthalidone is likely modest relative to other primary contributors (obesity, diabetes, alcohol, genetics), and a more clinically productive step is identifying and addressing dominant primary causes while considering whether replacing chlorthalidone with a metabolically neutral agent such as an ACE inhibitor, ARB, or CCB is warranted as a secondary measure
D) Thiazide diuretics cause severe hypertriglyceridemia exclusively through activation of pancreatic lipase inhibitors that impair dietary triglyceride clearance; stopping chlorthalidone will reduce triglycerides by more than 80% within 4 weeks
E) Thiazide diuretics are strongly indicated for hypertriglyceridemia above 500 mg/dL because chloride delivery to the distal tubule activates a compensatory renal lipase that clears circulating triglycerides; replacing chlorthalidone would worsen the triglyceridemia

ANSWER: C

Rationale:

This question asked you to accurately characterize thiazide metabolic effects and apply that characterization to a specific clinical decision. Option C is correct: thiazide and thiazide-like diuretics do cause modest increases in serum triglycerides, total cholesterol, and LDL cholesterol, as well as glucose intolerance and mild hyperuricemia — metabolic effects that are well-documented. The mechanisms are not fully understood but likely involve thiazide-induced insulin resistance (which increases hepatic VLDL production) and direct effects on lipid metabolism. However, these metabolic effects are dose-dependent, modest at standard doses, and generally considered acceptable given the cardiovascular outcome benefit demonstrated with thiazides in multiple outcome trials. In a patient with a triglyceride level of 680 mg/dL — markedly elevated and approaching the threshold for pancreatitis risk (typically above 500–1000 mg/dL) — the chlorthalidone is unlikely to be the dominant contributor. Primary causes of severe hypertriglyceridemia (familial hypertriglyceridemia, uncontrolled diabetes, hypothyroidism, obesity, excess alcohol, secondary causes) should be identified and addressed first. Replacing chlorthalidone with a metabolically neutral agent (ACE inhibitor, ARB, or CCB) is a reasonable secondary measure.

Option A: Option A is incorrect — thiazides do have established metabolic effects on lipid parameters.
Option B: Option B is incorrect — the mechanism of thiazide-induced dyslipidemia is not direct hepatic chloride channel activation; this is fabricated.
Option D: Option D is incorrect — thiazides do not primarily inhibit pancreatic lipase; the magnitude of effect described is grossly overstated.
Option E: Option E is incorrect and fabricated — chloride delivery to the distal tubule does not activate a renal lipase clearing circulating triglycerides.